Health Affairs, 25, no. 5 (2006): 1309-1317
doi: 10.1377/hlthaff.25.5.1309
© 2006 by Project HOPE
 
New Online
 * CBO Scoring Reform
 * Rising Insurance Rates
 * Health Care Investment
 * Consumers on Reform
 * Sen. Harkin on Child Obesity
 * Sen. Enzi: Fighting Obesity
This Article
* Abstract
* Full Text
* Submit a response to this article
Services
* E-mail this article to a friend
* Alert me to new issues of the journal

How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation
Reed et al. Health Affairs 25, no. 5 (2006): 1309

Online Technical Appendix

This Data Supplement consists of supplemental material that, because of space constraints, was not included with the published paper by Shelby D. Reed, Robert M. Califf, and Kevin A. Schulman, "How Changes in Drug-Safety Regulations Affect the Way Drug and Biotech Companies Invest in Innovation."

DISCLAIMER: This material is presented to supplement the published paper. Although it was part of the manuscript that was subjected to the scrutiny of external reviewers, it has not been edited or formatted by the editors of Health Affairs; the authors are solely responsible for any errors herein.

Files in this Data Supplement: